A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.一種可藉由包含治療劑及基質前驅物之液體混合物注射至鞘體中製造之固體藥物核心插入物。該注射可在低於室溫(subambient)之溫度下進行。該混合物經固化以形成固體藥物-基質核心。該治療劑在約室溫下可為液體，其在基質物質中形成小滴之分散液。例如，藉由切割該管使固體藥物核心之表面曝露，當植入患者中時，該固體藥物核心之曝露表面釋放治療量之治療劑。在一些實施例中，插入體抑制治療劑之釋放，例如以大體上不可滲透治療劑之物質，以使得治療量經由曝露表面釋放，從而避免治療劑釋放至非標靶組織。
